FIELD: pharmacology.
SUBSTANCE: invention relates to the use of cabozantinib or a pharmaceutically acceptable salt thereof for treatment of advanced renal cell carcinoma with metastases to bone or internal organs in a human patient who has previously received anti-angiogenic therapy.
EFFECT: effective agent in renal cell carcinoma treatment is proposed.
16 cl, 56 dwg, 56 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING THRICE-NEGATIVE BREAST CANCER | 2017 |
|
RU2757905C2 |
| METHOD OF TREATING DISSEMINATED RENAL CELL CARCINOMA | 2019 |
|
RU2715567C1 |
| NAZARTINIB FOR USE IN THE TREATMENT OF CNS METASTASIS | 2019 |
|
RU2795089C2 |
| USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
| METHOD OF TREATING RENAL CELL CARCINOMA | 2019 |
|
RU2712454C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2742312C1 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| USING ERIBULIN FOR TREATING BREAST CANCER | 2013 |
|
RU2689977C2 |
| ADMINISTERING HYPOXICALLY ACTIVATED PRODRUGS AND MEANS OF PREVENTING ANGIOGENESIS, FOR TREATING CANCER | 2011 |
|
RU2597844C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
